Changes to our company portfolio – MSD and Organon & Co. read more

Changes to our company portfolio

Please note that as of June 3rd 2021, MSD completed the spin-off of products from its women’s health, legacy brands, and biosimilars franchises into the new independent, publicly traded company Organon & Co.

For information on former MSD products now transferred to Organon & Co. please visit their website.



  • News Room


    20 September 2021 – MSD ANNOUNCEMENT

    MSD named as finalist in ‘Diverse Company’ category at National Diversity Awards from shortlist of over 64,000 entries across the UK – MSD Announcement

    15 September 2021 – MSD FEATURE STORY

    MSD for Mothers UK Ambassador Lead Natasha Philips explains why she is so passionate about her role in such a life-saving initiative

    10 June 2021 – MSD ANNOUNCEMENT

    MSD joins forces with other leaders from the technology, health, global development and academic sectors to announce the Alliance for Advancing Health Online

    06 May 2021 – MEDIA STATEMENT

    MSD Announces Election of Dr Fiona H. Marshall as Fellow of The Royal Society

    26 April 2021 – MSD ANNOUNCEMENT

    MSD Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025

    12 March 2021 – MSD ANNOUNCEMENT

    MSD named as ‘Outstanding Company of the Year’

    17 February 2021 – MEDIA STATEMENT

    MSD is spinning off products from its women’s health, legacy brands, and biosimilar franchises into a new, independent, publicly traded company called Organon

    9 February 2021 – MSD FEATURE STORY

    Inventing to Invest in Our Future, Dr Jill Richardson

    27 January 2021 – MEDIA STATEMENT

    MSD Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates

    5 October 2020 – MSD FEATURE STORY

    How do we support patients in a Covid-19 World? We think collaboration, flexibility and a focus on future pandemic preparedness is key

    8 September 2020 – MSD ANNOUNCEMENT

    MSD in the UK shortlisted for National Diversity Award

    24 August 2020 – MSD ANNOUNCEMENT

    MSD is spinning off products from its women’s health, legacy brands, and biosimilars franchises into a new independent, publicly traded company (“NewCo”)

    18 August 2020 – MEDIA STATEMENT

    MSD announces location of new state-of-the-art Discovery Research Centre and UK Headquarters in Central London

    15 July 2020 – MSD ANNOUNCEMENT

    MSD’s Therapy Area Community Grants Programme

    9th July 2020 – MSD ANNOUNCEMENT

    Addressing antibiotic resistance is more critical than ever. Here’s why.

    3rd July 2020 – MSD FEATURE STORY

    Diversity brings new ways of thinking

    1st July 2020 – MSD ANNOUNCEMENT

    MSD’s UK COVID-19 grants programme

    16th June 2020 – MSD FEATURE STORY

    Come as you are – employees bring their whole selves to work

    4th June 2020 – MSD ANNOUNCEMENT

    MSD Renews Commitment to Gavi

    27th May 2020 – MEDIA STATEMENT

    MSD Announces Multiple Scientific Efforts to Combat COVID-19

    18th May 2020 – MSD UPDATE

    Your questions answered: how MSD is responding to the global pandemic COVID-19

    3rd April 2020 – MSD FEATURE STORY

    Meet MSD doctor and volunteer Dr. Mo Ali

    23rd March 2020 – MSD ANNOUNCEMENT

    How MSD is responding to the global pandemic, COVID-19.

    31st January 2020 – MEDIA STATEMENT

    MSD is proud to announce we have been awarded Top Employer certification for the third year running.

    5th December 2019 – MEDIA STATEMENT

    MSD wins PMEA award for ‘Excellence in Corporate Reputation and Trust’

    25th November 2019 – MEDIA STATEMENT

    MSD announces Jo Bullen as new Executive Director of External Affairs for the UK

    12th November 2019 – MEDIA STATEMENT

    MSD’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union

    27th September 2019 – MEDIA STATEMENT

    New managing director announced for MSD in the UK and Ireland

    18th December 2018 – MEDIA STATEMENT

    MSD scientists get set to tackle diseases of ageing at the Francis Crick Institute

    For further UK media information, please telephone the External Affairs team on 01992 467272.

    For the Global MSD Newsroom, please click here

    The site is designed to provide members of the media with quick and easy access to recent information about the company. Here you will find product, research and development, corporate, and financial news releases, webcasts and executive speeches.